Official title and information are available only for Plus and Premium subscribers.
Patent Pending EZH2 over expression may promote cancer due to increase in histone methylation which silence the expression of tumor suppressor genes. An EZH2-targeting drug inhibits the progression of brain and prostate cancer in pre-clinical models.